BR0206919A - Derivados de fator de liberação de hormÈnio de crescimento de longa duração - Google Patents

Derivados de fator de liberação de hormÈnio de crescimento de longa duração

Info

Publication number
BR0206919A
BR0206919A BR0206919-9A BR0206919A BR0206919A BR 0206919 A BR0206919 A BR 0206919A BR 0206919 A BR0206919 A BR 0206919A BR 0206919 A BR0206919 A BR 0206919A
Authority
BR
Brazil
Prior art keywords
growth hormone
hormone release
long
release factor
term growth
Prior art date
Application number
BR0206919-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Dominique P Bridon
Nissab Boudjellab
Roger Leger
Martin Robitaille
Lucie Jette
Corinne Benquet
Original Assignee
Conjuchem Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Conjuchem Inc filed Critical Conjuchem Inc
Publication of BR0206919A publication Critical patent/BR0206919A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Obesity (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
BR0206919-9A 2001-02-02 2002-02-01 Derivados de fator de liberação de hormÈnio de crescimento de longa duração BR0206919A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26642401P 2001-02-02 2001-02-02
PCT/CA2002/000123 WO2002062844A2 (en) 2001-02-02 2002-02-01 Long lasting growth hormone releasing factor derivatives

Publications (1)

Publication Number Publication Date
BR0206919A true BR0206919A (pt) 2004-07-06

Family

ID=23014533

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0206919-9A BR0206919A (pt) 2001-02-02 2002-02-01 Derivados de fator de liberação de hormÈnio de crescimento de longa duração

Country Status (10)

Country Link
US (1) US7268113B2 (enExample)
EP (1) EP1355941A2 (enExample)
JP (3) JP2004520395A (enExample)
CN (2) CN1491233A (enExample)
AU (1) AU2002233082B2 (enExample)
BR (1) BR0206919A (enExample)
CA (1) CA2435563A1 (enExample)
EA (1) EA006484B1 (enExample)
WO (1) WO2002062844A2 (enExample)
ZA (1) ZA200305641B (enExample)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9425729D0 (en) * 1994-09-14 1995-02-22 British Telecomm Otical device
US6887470B1 (en) 1999-09-10 2005-05-03 Conjuchem, Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
US7601691B2 (en) 1999-05-17 2009-10-13 Conjuchem Biotechnologies Inc. Anti-obesity agents
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
PT1180121E (pt) * 1999-05-17 2004-03-31 Conjuchem Inc Peptidos insulinotropicos de longa duracao
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US20040266673A1 (en) * 2002-07-31 2004-12-30 Peter Bakis Long lasting natriuretic peptide derivatives
DK1360202T3 (da) * 2001-02-16 2008-09-22 Conjuchem Biotechnologies Inc Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser
EP1539959A2 (en) * 2002-09-18 2005-06-15 Centre Hospitalier de l'Université de Montréal (CHUM) Ghrh analogues
ES2347902T3 (es) * 2004-04-23 2010-11-22 Conjuchem Biotechnologies Inc. Canadian Corporation 4528590 Fase solida para uso en un procedimiento para la purificacion de conjugados de albumina.
US8039432B2 (en) * 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
AU2006329215A1 (en) * 2005-12-22 2007-06-28 Conjuchem Biotechnologies Inc. Process for the production of preformed conjugates of albumin and a therapeutic agent
US20090099074A1 (en) * 2007-01-10 2009-04-16 Conjuchem Biotechnologies Inc. Modulating food intake
US8889632B2 (en) 2007-01-31 2014-11-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
EP2508531B1 (en) 2007-03-28 2016-10-19 President and Fellows of Harvard College Stitched polypeptides
US20090088380A1 (en) * 2007-07-12 2009-04-02 Pierrette Gaudreau Ghrh analogs and therapeutic uses thereof
JP2011506442A (ja) * 2007-12-11 2011-03-03 コンジュケム バイオテクノロジーズ インコーポレイテッド インスリン分泌性ペプチド結合体の製剤
US20100267635A1 (en) * 2009-04-20 2010-10-21 Theratechonolgies Inc. Use of protease inhibitors and grf molecules in combination therapy
EP2421548A4 (en) * 2009-04-20 2012-09-26 Theratechnologies Inc USE OF (HEXENOYL TRANS-3) HGRF (1-44) NH2 AND SIMVASTATIN IN COMBINED TREATMENT
JP2013515081A (ja) * 2009-12-21 2013-05-02 アンブルックス，インコーポレイテッド 修飾されているブタのソマトトロピンポリペプチドおよびそれらの使用
WO2011153491A2 (en) 2010-06-03 2011-12-08 University Of Miami Agonists of growth hormone releasing hormone as effectors for survival and proliferation of pancreatic islets
SI2603600T1 (sl) 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetični makrocikli
BR112013027150A2 (pt) 2011-04-21 2017-06-06 Theratechnologies Inc thera
TW201806968A (zh) 2011-10-18 2018-03-01 艾利倫治療公司 擬肽巨環化合物
US9079974B2 (en) * 2011-12-21 2015-07-14 The University Of Miami GH-RH analogs with potent agonistic effects
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
KR102112373B1 (ko) 2012-02-15 2020-05-18 에일러론 테라퓨틱스 인코포레이티드 펩티드모방체 마크로사이클
MX349035B (es) 2012-05-17 2017-07-07 Extend Biosciences Inc Portadores para el suministro mejorado de farmaco.
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
WO2014071241A1 (en) 2012-11-01 2014-05-08 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
EP2934565B1 (en) 2012-12-21 2019-03-13 University of Miami Ghrh agonists for the treatment of ischemic disorders
EP2935317B1 (en) 2012-12-21 2019-03-27 University of Miami Ghrh agonists for islet cell transplantation and function and the treatment of diabetes
CN103897053B (zh) * 2012-12-25 2019-01-15 深圳先进技术研究院 化学修饰的胸腺肽α1及其合成方法
CN103665147A (zh) * 2013-11-26 2014-03-26 深圳翰宇药业股份有限公司 一种生长激素释放因子衍生物的合成方法
BR112017005598A2 (pt) 2014-09-24 2017-12-12 Aileron Therapeutics Inc macrociclos peptidomiméticos e usos dos mesmos
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US9585934B2 (en) 2014-10-22 2017-03-07 Extend Biosciences, Inc. Therapeutic vitamin D conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2016154058A1 (en) 2015-03-20 2016-09-29 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
EP3303378B1 (en) 2015-05-28 2021-04-21 Institut National de la Recherche Scientifique Inhibitors of prototypic galectin dimerization and uses thereof
JP7185874B2 (ja) 2015-11-18 2022-12-08 ヘルムホルツ－ツェントルン フュル インフェクティオンスフォルシュング ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗ウイルス剤としてのラビリントペプチン
EP3475294A1 (en) 2016-06-22 2019-05-01 The University of Rochester Cyclic peptide inhibitors of hedgehog proteins
WO2018085460A2 (en) * 2016-11-02 2018-05-11 Flagship Pioneering, Inc. Compositions and methods for cell delivery
CN108623694B (zh) * 2017-03-24 2021-09-17 北京市肿瘤防治研究所 血管内皮细胞生长因子受体拮抗肽f56的衍生物及应用
US20230022970A1 (en) 2019-12-19 2023-01-26 Transfert Plus, Société En Commandite Use of glial cell line-derived neurotrophic factor (gdnf) for the treatment of enteric neuropathies
PY2204506A (es) 2021-01-28 2022-08-30 Talem Therapeutics Llc Anticuerpos antiglicoproteína de espiga y su uso terapéutico
US12233115B2 (en) 2022-09-30 2025-02-25 Extend Biosciences, Inc. Long-acting parathyroid hormone
US20260092121A1 (en) 2022-10-14 2026-04-02 Talem Therapeutics Llc Anti-trkb/cd3 antibodies and uses thereof

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4411890A (en) * 1981-04-14 1983-10-25 Beckman Instruments, Inc. Synthetic peptides having pituitary growth hormone releasing activity
US4462941A (en) * 1982-06-10 1984-07-31 The Regents Of The University Of California Dynorphin amide analogs
US4517181A (en) * 1982-09-15 1985-05-14 The Salk Institute For Biological Studies Mammalian PGRF
US4529595A (en) * 1983-01-13 1985-07-16 The Salk Institute For Biological Studies GRF Analogs
US4563352A (en) * 1982-10-04 1986-01-07 The Salk Institute For Biological Studies Human pancreatic GRF
US4595676A (en) * 1983-04-26 1986-06-17 The Salk Institute For Biological Studies Rat hypothalamic GRF
US4518586A (en) * 1983-01-13 1985-05-21 The Salk Institute For Biological Studies GRF Analogs III
US4628043A (en) * 1983-04-26 1986-12-09 The Salk Institute For Biological Studies Hypothalamic GRF agonists
US5416073A (en) * 1983-08-10 1995-05-16 The Adminstrators Of The Tulane Educational Fund Growth hormone-releasing peptides and method of treating animals, therewith
US4610976A (en) * 1983-08-29 1986-09-09 The Salk Institute For Biological Studies Porcine GRF
US4605643A (en) * 1984-03-02 1986-08-12 The Salk Institute For Biological Studies Ovine GRF
US4585756A (en) * 1983-10-12 1986-04-29 The Salk Institute For Biological Studies Bovine GRF
US4626523A (en) * 1983-09-13 1986-12-02 The Salk Institute For Biological Studies GRF analogs II
US4528190A (en) * 1983-10-25 1985-07-09 The Salk Institute For Biological Studies GRF Analogs IV
DE3579911D1 (de) * 1984-12-24 1990-10-31 Sumitomo Pharma Stabiles grf-praeparat.
CA1271600A (en) 1985-01-07 1990-07-10 David Howard Coy Growth hormone-releasing peptides and method of treating mammals therewith
US4734399A (en) * 1985-08-06 1988-03-29 Hoffmann-La Roche Inc. Growth hormone releasing factor analogs
US4689318A (en) * 1985-08-29 1987-08-25 The Salk Institute For Biological Studies GRF analogs
US4843064A (en) * 1987-01-13 1989-06-27 The Salk Institute For Biological Studies GRF analogs V
US4784987A (en) * 1987-01-13 1988-11-15 The Salk Institute For Biological Studies GRF analogs VI
AU628322B2 (en) 1988-01-28 1992-09-17 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
AU637316B2 (en) 1988-01-28 1993-05-27 Eastman Kodak Company Polypeptide compounds having growth hormone releasing activity
US5756458A (en) * 1989-06-16 1998-05-26 Pharmacia & Upjohn Company Stabilized potent GRF analogs
DK608589D0 (da) 1989-12-01 1989-12-01 Holm Arne Kemisk fremgangsmaade
US5843440A (en) * 1990-10-03 1998-12-01 Redcell Canada, Inc. Cellular and serum protein anchors for modulating pharmacokinetics
US5612034A (en) * 1990-10-03 1997-03-18 Redcell, Inc. Super-globuling for in vivo extended lifetimes
DK0578728T3 (da) * 1991-04-05 1999-04-12 Genentech Inc Inhibitorer for aggregering af blodplader, hvilke inhibitorer har høj specificitet for GP IIbIIIa
CA2084061A1 (en) * 1991-04-09 1992-10-10 Arthur M. Felix Growth hormone releasing factor analogs
DE4122210C2 (de) 1991-07-04 1999-04-01 Deutsches Krebsforsch Konjugate aus tumoraktiver Verbindung und Serumalbumin sowie Verfahren zu deren Herstellung und ihre Verwendung
US5663146A (en) 1991-08-22 1997-09-02 Administrators Of The Tulane Educational Fund Polypeptide analogues having growth hormone releasing activity
CZ281630B6 (cs) 1992-06-12 1996-11-13 Des-Tyr Dynorphin Partnership Analogy des-tyr dynorfinu
EP0602290B1 (en) 1992-12-04 1999-08-25 ConjuChem, Inc. Antibody-conjugated Hepatitis B surface antigen and use thereof
US5580853A (en) * 1994-03-22 1996-12-03 New England Deaconess Hospital Modified polypeptides with increased biological activity
AU7637394A (en) 1994-08-26 1996-03-22 Avram Goldstein Analgesic method with dynorphin analogues truncated at the n-terminus
US6184201B1 (en) * 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5654276A (en) * 1995-06-07 1997-08-05 Affymax Technologies N.V. Peptides and compounds that bind to the IL-5 receptor
EP0851767A1 (en) * 1995-09-21 1998-07-08 Quadrant Healthcare (UK) Limited Transcytosis vehicles and enhancers for drug delivery
GB9526733D0 (en) 1995-12-30 1996-02-28 Delta Biotechnology Ltd Fusion proteins
ES2197258T3 (es) * 1996-01-11 2004-01-01 PHARMACIA & UPJOHN COMPANY Formulacion acuosa de liberacion prolongada que comprende el factor de liberacion de la hormona de crecimiento bovino.
EP0929576A1 (en) 1996-08-30 1999-07-21 Novo Nordisk A/S Glp-2 derivatives
ATE406577T1 (de) 1997-11-07 2008-09-15 Conjuchem Biotechnologies Inc Methoden zum screening von affinitätsmarker- bibliotheken
DE69812727D1 (de) 1997-11-07 2003-04-30 Conjuchem Inc Opioid-konjugate mit endogenen Trägerproteinen
IL133053A0 (en) 1998-03-23 2001-03-19 Conjuchem Inc Local delivery of long lasting therapeutic agents
PT1180121E (pt) 1999-05-17 2004-03-31 Conjuchem Inc Peptidos insulinotropicos de longa duracao
AU765753B2 (en) 1999-05-17 2003-09-25 Conjuchem Biotechnologies Inc. Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
DE19926154A1 (de) 1999-06-09 2000-12-14 Ktb Tumorforschungs Gmbh Verfahren zur Herstellung einer injizierbaren Arzneimittelzubereitung
DE19926475A1 (de) 1999-06-10 2000-12-14 Ktb Tumorforschungs Gmbh Träger-Pharmaka-Konjugate
DE10012120A1 (de) 2000-03-13 2001-09-27 Ktb Tumorforschungs Gmbh Therapeutische und diagnostische Ligandensysteme mit Transportmolekülbindenden Eigenschaften und diese enthaltende Arzneimittel
CA2786794C (en) 2004-03-23 2017-09-12 Complex Biosystems Gmbh Aromatic polymeric cascade prodrug linker reagent

Also Published As

Publication number Publication date
EA200300856A1 (ru) 2004-08-26
ZA200305641B (en) 2004-05-25
JP2008106073A (ja) 2008-05-08
JP2009024017A (ja) 2009-02-05
CA2435563A1 (en) 2002-08-15
US7268113B2 (en) 2007-09-11
CN1491233A (zh) 2004-04-21
WO2002062844A2 (en) 2002-08-15
EP1355941A2 (en) 2003-10-29
EA006484B1 (ru) 2005-12-29
US20030073630A1 (en) 2003-04-17
CN101696240A (zh) 2010-04-21
WO2002062844A3 (en) 2003-08-21
AU2002233082B2 (en) 2005-11-10
JP2004520395A (ja) 2004-07-08

Similar Documents

Publication Publication Date Title
EA200300856A1 (ru) Долгоживущие производные рилизинг-фактора гормона роста
AU2003299391A1 (en) Edible, chewable object for carnivorous pets and method of controlling the hygiene of the oral cavity of said animals, using one such object
BR0007597A (pt) Composição hipoalergênica contendo peptìdios tolerogênicos induzindo tolerância oral
DK1025124T3 (da) Human interferon-alfa-analoge med lav toksicitet
DE69725052D1 (de) Verbindungsstift für mehrteiliges orthopädisches Implantat
BRPI0519170A8 (pt) formulações de hormônio de crescimento humano que compreendem um aminoácido não naturalmente codificado
BRPI0412526A (pt) composto, uso de um composto, composição farmacêutica, formulação em aerossol farmacêutica, e, método para o tratamento de um paciente humano ou animal com uma condição anti-inflamatória e/ou alérgica
DK1353614T3 (da) Massivt modulsystem
CY1108027T1 (el) Νεα συμπλοκα χρωμιου (iii) με α-αμινοξεα
DK1792610T3 (da) Terapeutiske bioadhæsive systemet med langvarig frigivelse
EP1490483A4 (en) IN VIVO INSTALLATION OF NON-NATURAL AMINO ACIDS
PT885904E (pt) Peptidos como agonistas e/ou inibidores de formacao amiloide e/ou citotoxicidade e a sua utilizacao contra a doenca de alzheimer diabetes mellitus tipo ii e encefalopatia espongiforme
BR9811094A (pt) Agente terapêutico para tumores linfáticos
BR0004335A (pt) Substituicão aloplástica para osso longo
NO20015176D0 (no) Anvendelse av kreatin som fortilsats
BRPI0412332A (pt) método para aumentar nìveis de antioxidante no sangue em um felino, e, composição para dieta adequada para alimentar animais de companhia jovens
SE0203787D0 (sv) Fixtur
BR0009472A (pt) Antagonistas de lhrh com propriedades desolubilidade aperfeiçoadas
ES2422081T3 (es) Péptido Ser-Ser-Ser-Arg y sus utilizaciones medicinales
AR003687A1 (es) Marca para oreja de animal
EP1401431A4 (en) HUMAN GROWTH HORMONE ANTAGONISTS
BR9106676A (pt) Peptideo,processo para promover a liberacao de niveis de hormonio de crescimento em um animal,composicao farmaceutica para promover a liberacao de niveis de hormonio de crescimento em animais,uso do composto e processo para promover a liberacao e elevacao de niveis de hormonio de crescimento no sangue
HN1998000141A (es) Composicion farmaceutica antimastitica a base de extractos de origen natural y procedimientom para fabricarla.
EP1454629A3 (en) Insulinotrophic agent based on preproglucagon
AU2003301744A1 (en) Fracture pin

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: CONJUCHEM BIOTECHNOLOGIES INC. (CA)

Free format text: TRANSFERIDO DE: CONJUCHEM INC.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal: dismissal of application maintained